|
1
|
Kawai K, Finn AV and Virmani R:
Subclinical Atherosclerosis Collaborative. Subclinical
atherosclerosis: Part 1: What is it? Can it be defined at the
histological level? Arterioscler Thromb Vasc Biol. 44:12–23.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Koelwyn GJ, Corr EM, Erbay E and Moore KJ:
Regulation of macrophage immunometabolism in atherosclerosis. Nat
Immunol. 19:526–537. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wu J, He S, Song Z, Chen S, Lin X, Sun H,
Zhou P, Peng Q, Du S, Zheng S and Liu X: Macrophage polarization
states in atherosclerosis. Front Immunol.
14(1185587)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ma C, Li Y, Tian M, Deng Q, Qin X, Lu H,
Gao J, Chen M, Weinstein LS, Zhang M, et al: Gsα regulates
macrophage foam cell formation during atherosclerosis. Circ Res.
134:e34–e51. 2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kunjathoor VV, Febbraio M, Podrez EA,
Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF and
Freeman MW: Scavenger receptors class A-I/II and CD36 are the
principal receptors responsible for the uptake of modified low
density lipoprotein leading to lipid loading in macrophages. J Biol
Chem. 277:49982–49988. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
O'Donoghue ML, Giugliano RP, Wiviott SD,
Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH,
López JAG, et al: Long-term evolocumab in patients with established
atherosclerotic cardiovascular disease. Circulation. 146:1109–1119.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Grundy SM, Stone NJ, Bailey AL, Beam C,
Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S,
Faiella-Tommasino J, Forman DE, et al: 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline
on the management of blood cholesterol: Executive summary: A report
of the American college of cardiology/American heart association
task force on clinical practice guidelines. Circulation.
139:e1046–e1081. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mach F, Baigent C, Catapano AL, Koskinas
KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V,
Ference BA, et al: 2019 ESC/EAS guidelines for the management of
dyslipidaemias: Lipid modification to reduce cardiovascular risk.
Eur Heart J. 41:111–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nicholls SJ, Kataoka Y, Nissen SE, Prati
F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JPR, Hermanides
RS, et al: Effect of evolocumab on coronary plaque phenotype and
burden in statin-treated patients following myocardial infarction.
JACC Cardiovasc Imaging. 15:1308–1321. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Keam SJ: Tafolecimab: First approval.
Drugs. 83:1545–1549. 2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
White HD, Steg PG and Schwartz GG:
Myocardial infarction and evolocumab. JAMA Cardiol. 6:1220–1221.
2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sabatine MS, Giugliano RP, Keech AC,
Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T,
Wasserman SM, et al: Evolocumab and clinical outcomes in patients
with cardiovascular disease. N Engl J Med. 376:1713–1722.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lu L, Sun X, Qin Y and Guo X: The
signaling pathways involved in the antiatherosclerotic effects
produced by Chinese herbal medicines. BioMed Res Int.
2018(5392375)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hummelgaard S, Vilstrup JP, Gustafsen C,
Glerup S and Weyer K: Targeting PCSK9 to tackle cardiovascular
disease. Pharmacol Ther. 249(108480)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu X, Zheng T, Zhang Y, Zhao Y, Liu F,
Dai S, Zhang M, Zhang W, Zhang C, Zhang M and Li X: Endothelial
dickkopf-1 promotes smooth muscle cell-derived foam cell formation
via USP53-mediated deubiquitination of SR-A during atherosclerosis.
Int J Biol Sci. 20:2943–2964. 2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cheng W, Shu M, Kuang L, Bai X, Jia X,
Zhao Y, Lu Y, Zhu L, Wang L, Zhu Y, et al: Scavenger receptor a
mediates glycated LDL transcytosis across endothelial cells to
promote atherosclerosis. Int J Biol Macromol.
235(123836)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zheng S, Huang H, Li Y, Wang Y, Zheng Y,
Liang J, Zhang S, Liu M and Fang Z: Yin-xing-tong-mai decoction
attenuates atherosclerosis via activating PPARγ-LXRα-ABCA1/ABCG1
pathway. Pharmacol Res. 169(105639)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang H, Yang Y, Sun X, Tian F, Guo S, Wang
W, Tian Z, Jin H, Zhang Z and Tian Y: Sonodynamic therapy-induced
foam cells apoptosis activates the phagocytic
PPARγ-LXRα-ABCA1/ABCG1 pathway and promotes cholesterol efflux in
advanced plaque. Theranostics. 8:4969–4984. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Frambach SJCM, de Haas R, Smeitink JAM,
Rongen GA, Russel FGM and Schirris TJJ: Brothers in arms: ABCA1-
and ABCG1-mediated cholesterol efflux as promising targets in
cardiovascular disease treatment. Pharmacol Rev. 72:152–190.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang S, Xu P, Zhu Z, Zhou L, Li J, Zhou
R, Kan Y, Li Y, Yu X, Zhao J, et al: Acetylation of
p65Lys310 by p300 in macrophages mediates
anti-inflammatory property of berberine. Redox Biol.
62(102704)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mao H, Zhao X and Sun SC: NF-κB in
inflammation and cancer. Cell Mol Immunol. 22:811–839.
2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kaszycki J and Kim M: Epigenetic
regulation of transcription factors involved in NLRP3 inflammasome
and NF-kB signaling pathways. Front Immunol.
16(1529756)2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chu C, Ru H, Chen Y, Xu J, Wang C and Jin
Y: Gallic acid attenuates LPS-induced inflammation in Caco-2 cells
by suppressing the activation of the NF-κB/MAPK signaling pathway.
Acta Biochim Biophys Sin (Shanghai). 56:905–915. 2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kambhampati V, Eedara A and Andugulapati
SB: Yohimbine treatment improves pulmonary fibrosis by attenuating
the inflammation and oxidative stress via modulating the MAPK
pathway. Biochem Pharmacol. 230(116613)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Seidah NG and Prat A: The multifaceted
biology of PCSK9. Endocr Rev. 43:558–582. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Peng Z, Lv SJ, Chen H, Rao H, Guo Z, Wan
Q, Yang J, Zhang Y, Liu DP, Chen HZ and Wang M: Disruption of PCSK9
suppresses inflammation and attenuates abdominal aortic aneurysm
formation. Arterioscler Thromb Vasc Biol. 45:e1–e14.
2025.PubMed/NCBI View Article : Google Scholar
|
